Clinical trials: Moderate-to-severe Atopic Dermatitis
Dermatitis, Atopic
To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis
This is a Phase II, randomized, double-blind, placebo-controlled study in subjects with moderate to severe atopic dermatitis.
- Trial name
- SOLARES-AD-1 (NCT04684485)
- Testing
- SCD-044_Dose 1, SCD-044_Dose 2, SCD-044_Dose 3
- Where
- 58 sites in United States, El Salvador and 3 more
- Volunteers
- 250 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Atopic Dermatitis
Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)
Primary objective: To evaluate the efficacy of tralokinumab compared with placebo in treating moderate to severe atopic dermatitis (AD).
- Trial name
- ECZTRA 1 (NCT03131648)
- Testing
- Tralokinumab
- Where
- 123 sites in United States, France and 3 more
- Volunteers
- 802 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)
The purpose of this trial is to evaluate the efficacy and safety of tralokinumab administered as subcutaneous (SC) injection by an autoinjector in adults and adolescents (age 12 to 17 years) with moderate-to-severe atopic…
- Trial name
- INJECZTRA (NCT05194540)
- Testing
- Tralokinumab
- Where
- 29 sites in United States
- Volunteers
- 136 people
- Sponsor
- LEO Pharma
Moderate-to-Severe Atopic Dermatitis
Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with…
- Trial name
- NCT03989349
- Testing
- Nemolizumab
- Where
- 138 sites in United States, Belgium and 9 more
- Volunteers
- 787 people
- Sponsor
- Galderma R&D
Atopic Dermatitis
Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.
This is a randomized, double-blind, placebo-controlled, parallel-group study which is 16 weeks in duration. The study is designed to evaluate the safety and efficacy of lebrikizumab when used in combination with topical…
- Trial name
- ADhere (NCT04250337)
- Testing
- Lebrikizumab, Topical Corticosteroid
- Where
- 63 sites in United States, Canada and 2 more
- Volunteers
- 228 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab with/without Topical Corticosteroid Treatment in Participants with Moderate-to-Severe Atopic Dermatitis.
- Trial name
- NCT06280716
- Testing
- Lebrikizumab, Topical Corticosteroid
- Where
- 46 sites in China, South Korea
- Volunteers
- 301 people
- Sponsor
- Eli Lilly and Company
Dermatitis, Atopic
Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
B7451013 is a Phase 3 study to evaluate PF-04965842 in patients aged 12 years and older with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis.
- Trial name
- JADE Mono-2 (NCT03575871)
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg
- Where
- 115 sites in United States, Australia and 11 more
- Volunteers
- 391 people
- Sponsor
- Pfizer
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis
This study will assess the efficacy and safety of MSTT1041A (astegolimab) in participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT03747575
- Testing
- MSTT1041A
- Where
- 21 sites in United States, Germany and 1 more
- Volunteers
- 65 people
- Sponsor
- Genentech, Inc.
Atopic Dermatitis
Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)
This was a 32-week, randomized, double-blind, placebo-controlled, parallel-group study assessing immunization responses to vaccination in adults with moderate to severe atopic dermatitis who are treated with subcutaneous…
- Trial name
- NCT02210780
- Testing
- Dupilumab
- Where
- 42 sites in United States
- Volunteers
- 194 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
The primary objective of the study is to assess the efficacy of REGN3500 monotherapy in Atopic dermatitis (AD), as well as understand the dose-response relationship, compared with placebo treatment, in adult patients with…
- Trial name
- NCT03738423
- Testing
- REGN3500
- Where
- 89 sites in United States, Australia and 9 more
- Volunteers
- 129 people
- Sponsor
- Regeneron Pharmaceuticals
Dermatitis Atopic
Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis
Primary Objective: Evaluate changes in skin barrier function with transepidermal water loss (TEWL) assessed after skin tape stripping (STS) in predefined lesional skin in pediatric participants with moderate to severe atopic…
- Trial name
- PELISTAD (NCT04718870)
- Testing
- Dupilumab SAR231893
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Sanofi
Atopic Dermatitis
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
- Trial name
- NCT03607422
- Testing
- Upadacitinib
- Where
- 196 sites in United States, Australia and 21 more
- Volunteers
- 912 people
- Sponsor
- AbbVie
Atopic Dermatitis
Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
This is an open-label, single arm study of 52 weeks duration. The study will assess the safety and efficacy of lebrikizumab in adolescent participants (≥12 to <18 years weighing ≥40 kilograms) with moderate-to-severe atopic…
- Trial name
- ADore (NCT04250350)
- Testing
- Lebrikizumab
- Where
- 70 sites in United States, Australia and 2 more
- Volunteers
- 206 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis
This is an up to 22-week clinical study in adult participants with moderate to severe atopic dermatitis (AD). The purpose of the study is to test a new tablet (LEO 152020) to see if it improves AD and what the side effects are…
- Trial name
- NCT05117060
- Testing
- LEO 152020 tablet
- Where
- 45 sites in United States, Australia and 6 more
- Volunteers
- 216 people
- Sponsor
- JW Pharmaceutical
Atopic Dermatitis
A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India
The purpose of this clinical trial is to learn about the safety and how well the study medicine (called Abrocitinib) works for the potential treatment of moderate to severe Atopic Dermatitis (AD) in India.
- Trial name
- NCT05375929
- Testing
- Abrocitinib 100 mg, Abrocitinib 200 mg
- Where
- 15 sites in India
- Volunteers
- 200 people
- Sponsor
- Pfizer
Atopic Dermatitis
Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients
The purpose of this study is to determine whether orally administered DS107 (1g and 2g doses) is effective in the treatment of moderate to severe atopic dermatitis.
- Trial name
- NCT02864498
- Testing
- DS107
- Where
- 2 sites in United States, South Africa
- Volunteers
- 321 people
- Sponsor
- DS Biopharma
Chronic Hand Eczema
Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)
This was a 16-week study in adult participants with chronic hand eczema (CHE). The participants visited the clinic regularly to have the study doctor assess their CHE and to answer questions about itch, pain, CHE symptoms, and…
- Trial name
- DELTA 2 (NCT04872101)
- Testing
- Delgocitinib cream, Cream vehicle
- Where
- 50 sites in Belgium, Canada and 5 more
- Volunteers
- 473 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis
This is a study for adults (18-75 years) who have successfully completed treatment either with Dupilumab or with Upadacitinib in the study M16-046.
- Trial name
- NCT04195698
- Testing
- Upadacitinib
- Where
- 116 sites in United States, Australia and 20 more
- Volunteers
- 475 people
- Sponsor
- AbbVie
Atopic Dermatitis, Eczema
A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis
A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis
- Trial name
- NCT04021862
- Testing
- Bermekimab Monoclonal Antibody
- Where
- 17 sites in United States
- Volunteers
- 87 people
- Sponsor
- Janssen Research & Development, LLC
Atopic Dermatitis
Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)
The purpose and (primary) objectives of this study are to evaluate the efficacy, safety, and tolerability of TS-022 in adults with atopic dermatitis who have moderate to very severe pruritus (itching), following a 28-day regimen…
- Trial name
- NCT00914186
- Testing
- TS022, Vehicle
- Where
- 15 sites in United States
- Volunteers
- 122 people
- Sponsor
- Taisho Pharmaceutical R&D Inc.